Business
BioElectronics Earns CE Mark for the ActiPatch and RecoveryRx -- Drug-Free Pain Therapy Devices
BioElectronics Earns CE Mark for the ActiPatch and RecoveryRx -- Drug-Free Pain Therapy Devices.
About this update from Bioelectronics Corp.
[{"type":"text","content":"\n Opens the Sales Market for 33+ Additional Countries FREDERICK, MD, Nov. 12, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce that it has received the CE (Conformité Européenne) Mark for its ActiPatch® and RecoveryRx® Pulsed Shortwave Therapy (PSWT) medical devices. The ActiPatch is indicated for the treatment of general musculoskeletal/soft-tissue pain, while the RecoveryRx is indicated for the treatment of postoperative pain. These wearable devices can now be sold over the counter in 33 European Union (EU) countries, and many other non-EU countries like Australia that recognize the CE mark. Keith Nalepka, VP Sales and Marketing for BioElectronics, said: “This is the latest in a series of wins for the Company. The CE mark will allow us to resume fulfilling substantial orders for existing international partners, and close pending deals that were contingent on the CE mark. We are excited that 2021 will be a great year of sales for the Company.” The certification for the CE mark is valid until May 2024, and the Company’s updated quality management system will ensure prompt recertification. About BioElectronics Corporation BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Therapy for postoperative pain and chronic wound care. Forward Looking Statements Certain information set forth in this email contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s visi...